Avalo Therapeutics Inc (AVTX)

Avalo Therapeutics' stock price has experienced significant movement in the past six months, with a 94.87% increase from November 27, 2024, to November 26, 2025, and an 88.32% increase over the last year. The stock was up 13.31% compared to the previous week and 5.91% over the last month as of November 25, 2025. The company reported its Q3 2025 earnings on November 6, 2025, with an EPS of -$2.19, missing analysts' expectations. Increased R&D expenses and higher G&A costs have impacted the company's financials. The company has bolstered its financial position through the full exercise of private placement warrants, generating $69.4 million, and received $58.1 million from the exercise of warrants issued in early 2024, extending its cash runway potentially into 2027.

As a clinical-stage biotechnology company, Avalo Therapeutics does not currently have commercialized products or services, and therefore, traditional "demand seasonality" for its products is not applicable. Historically, buying Avalo Therapeutics Inc (AVTX.O) stock in June has shown the highest probability of a positive return (63.64%), while December has the lowest probability (20.00%).

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune dysregulation and inflammatory diseases in the United States. Their lead asset is AVTX-009, a humanized monoclonal antibody targeting interleukin-1β (IL-1β), currently in a Phase 2 clinical trial for hidradenitis suppurativa (HS), with top-line data expected in 2026. The company previously divested or discontinued quisovalimab and AVTX-008 as part of a strategic restructuring. Avalo Therapeutics relies on equity financing and potential collaborations to fund its operations.

Avalo Therapeutics, Inc. is headquartered in Rockville, Maryland, and has an address in Wayne, Pennsylvania, indicating a primary operational focus within the United States.

Avalo Therapeutics has generally received positive sentiment from analysts, with a consensus rating of "Moderate Buy" and "Strong Buy". Investor confidence has also been noted, particularly ahead of the LOTUS data readout for AVTX-009. However, there have been some concerns regarding a "concerning incidence of neutropenia in its clinical trials" and the competitiveness of its therapies.

Avalo Therapeutics, Inc. has a diverse ownership base, with institutional investors holding the largest block of shares at 34%, followed by the general public at 19%, and hedge funds at 23%. Insiders also own shares, valued at US$6.8 million. Major institutional owners include BVF Partners L.P., OrbiMed Advisors LLC, Nantahala Capital Management, LLC, Armistice Capital LLC, Point72 Asset Management, L.P., Affinity Asset Advisors, LLC, Caligan Partners LP, Balyasny Asset Management Llc, Silverarc Capital Management, Llc, Vanguard Group Inc, and Ra Capital Management, L.p. Six of the top shareholders collectively account for approximately 51% of the company's shares.